X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndromeXOLREMDI Phase 3 4WHIM clinical trial data published online in..
U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndromeXOLREMDI Phase 3 4WHIM clinical trial data published online in..
· Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of..
EQS-News: EPH Group AG / Key word(s): Personnel
EPH Group AG: New appointments to the Management Board and Supervisory..